ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX) has announced an Investor Day program scheduled for Tuesday, April 15, 2025, at 10:00 am PDT. The event will feature comprehensive updates on:

• Business operations and regulatory advances
• Clinical programs including bladder cancer, non-small cell lung cancer, and metastatic pancreatic cancer trials
• Natural killer (NK) cell therapy program and Lynch syndrome accrual
• Discussions on virally induced cancers and Long-COVID

The event will include fireside chats with distinguished key opinion leaders and a presentation by Dr. Patrick Soon-Shiong on the company's technology platforms. The in-person event will be held in El Segundo, California, with space availability, requiring advance RSVP. A live stream option will be available for remote attendance.

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company’s business operations, U.S. and global regulatory advances of its clinical-stage products, with fireside chats hosted by Dr. Patrick Soon-Shiong and key opinion leaders involved in the company’s research programs.

The discussions will include clinical and regulatory updates on the company’s bladder cancer program, regenerative medicine advanced therapy (RMAT) designations, including results on non-small cell lung cancer (NSCLC) and metastatic pancreatic cancer trials, as well as lymphopenia rescue data related to these trials (Cancer BioShield).

In addition, updates will be provided on the natural killer (NK) cell therapy program, the Lynch syndrome accrual and fireside chats on virally induced cancers, including discussions on Long-COVID.

The key opinion leaders participating in the fireside chats with ImmunityBio leadership include:

• Dr. Christopher Pieczonka – Chief Executive Officer, Associated Medical Professionals of New York & Corporate Director of Clinical Research of US Urology Partners
• Dr. Steven Finkelstein – National Director of Radiation Oncology, US Urology Partners. Director of the Center of Advanced Radiation Excellence (CARE) and Director Radiation Oncology Research
• Dr. Mark Lanasa – Senior Vice President, Chief Medical Officer, Solid Tumors, BeiGene
• Dr. Jennifer Buell – President & Chief Executive Officer, MiNK Therapeutics
• Dr. Krishnansu Tewari – Gynecologic Oncology, Obstetrics & Gynecology at UC Irvine Health
• Dr. David Kerr - Professor of Cancer Medicine Genetics and Genomics, University of Oxford
• Dr. Timothy Heinrich – Professor, School of Medicine UC San Francisco
• Dr. Carlos Cardo-Cardon – Chairman for the Mount Sinai Health System Dept. of Pathology

Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials.

The program will feature a presentation by ImmunityBio Founder, Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, outlining the fundamental science underpinning the company’s technology platforms. This technology harnesses the immune system to deliver long-term disease protection and prevention.

This limited space event will be held in person in El Segundo, California. Individuals wishing to attend in person must RSVP in advance via email (investorday2025@immunitybio.com). The event will also be live-streamed.

The live stream can be found at:

https://viavid.webcasts.com/starthere.jsp?ei=1713505&tp_key=40dc7065b5

Participant Listening (Listen Only)

1-844-539-3703 or 1-412-652-1273

About ImmunityBio

ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit ImmunityBio.com (Founder’s Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the anticipated date, time, location, subject matter and other information regarding the key opinion leader and investor meeting described herein, anticipated attendees and presenters at the foregoing, ImmunityBio’s potential growth trajectory and business prospects, ImmunityBio’s beliefs regarding the potential for its approach to revolutionize cancer care, ImmunityBio’s manufacturing and production capabilities, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA and use in cancer vaccines and across multiple tumor types, and ImmunityBio’s approved product and its and its collaborators’ investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “is,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks, uncertainties and potential changes in circumstances that may impact ImmunityBio’s ability to hold the investor day program as described herein and the anticipated presenters’ ability to attend the same, (ii) risks and uncertainties regarding commercial launch execution, success and timing, (iii) risks and uncertainties related to the regulatory submission, filing and review process and the timing thereof, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) whether clinical trials will result in registrational pathways, (vi) whether clinical trial data will be accepted by regulatory agencies, (vii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (viii) potential delays in product availability and regulatory approvals, (ix) the risks and uncertainties associated with third party collaborations and agreements, (x) ImmunityBio’s ability to retain and hire key personnel, (xi) ImmunityBio’s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xiii) ImmunityBio’s ability to successfully commercialize its approved product and product candidates, (xiv) ImmunityBio’s ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xv) ImmunityBio’s ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250407918834/en/

ImmunityBio Contacts:

Investors

Hemanth Ramaprakash, PhD, MBA

ImmunityBio, Inc.

+1 858-746-9289

Hemanth.Ramaprakash@ImmunityBio.com

Media

Sarah Singleton

ImmunityBio, Inc.

+1 415-290-8045

Sarah.Singleton@ImmunityBio.com

Source: ImmunityBio, Inc.

FAQ

When and where is ImmunityBio's (IBRX) 2025 Investor Day taking place?

ImmunityBio's Investor Day is scheduled for Tuesday, April 15, 2025, at 10:00 am PDT in El Segundo, California.

What clinical programs will be discussed at ImmunityBio's (IBRX) 2025 Investor Day?

The event will cover updates on bladder cancer, non-small cell lung cancer, metastatic pancreatic cancer trials, NK cell therapy, Lynch syndrome, and virally induced cancers including Long-COVID.

How can investors attend ImmunityBio's (IBRX) 2025 Investor Day?

Investors can attend either in person (RSVP required via investorday2025@immunitybio.com) or virtually through a live stream webcast.

Which key opinion leaders will be present at ImmunityBio's (IBRX) 2025 Investor Day?

Speakers include Dr. Christopher Pieczonka, Dr. Steven Finkelstein, Dr. Mark Lanasa, Dr. Jennifer Buell, Dr. Krishnansu Tewari, Dr. David Kerr, Dr. Timothy Heinrich, and Dr. Carlos Cardo-Cardon.

What technology updates will be presented at ImmunityBio's (IBRX) 2025 Investor Day?

Dr. Patrick Soon-Shiong will present on the company's immune system-focused technology platforms designed for long-term disease protection and prevention.